- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07544134
Areola Preservation in NSM With Nipple Involvement (APRESERVE-1)
Oncologic Safety and Aesthetic Outcomes of Areola Preservation With Simultaneous Nipple Reconstruction in Nipple-Sparing Mastectomy With Intraoperative Nipple Involvement: A Single-Center, Prospective, Exploratory Study
Background:
During nipple-sparing mastectomy (a surgery that removes breast tissue but keeps the nipple and areola), doctors test the tissue behind the nipple right away. If cancer cells are found in this nipple tissue, current guidelines say the entire nipple and areola must be removed. However, research suggests that when the nipple is involved, the surrounding pigmented skin (the areola) is very rarely affected by cancer. Removing it might be unnecessary and leads to a worse cosmetic outcome, which can impact a woman's self-image and quality of life. Currently, there is no prospective study to guide whether the areola can be safely preserved in this specific situation.
Purpose:
This is a pilot study that aims to explore the feasibility, safety, and early outcomes of a new surgical procedure: preserving the areola and performing immediate nipple reconstruction when cancer is found in the nipple during surgery.
Study Plan:
This is a single-arm, single-center, prospective, exploratory study. Women with early-stage breast cancer who are scheduled for a nipple-sparing mastectomy will be invited. Only if cancer is confirmed in the nipple during their surgery will they be enrolled into the single test group. In this group:
The nipple is removed.
A small ring of tissue from under the areola is tested immediately (second frozen section). If this ring shows no cancer, the areola skin is preserved.
A new nipple is created during the same operation using a local skin flap technique (purse-string suture).
All patients will have immediate breast reconstruction.
We plan to include about 40-60 patients at one hospital. Patients will be closely followed for 3 years with regular check-ups and scans to monitor for any cancer recurrence or complications.
What We Will Measure (Exploratory Endpoints):
Safety & Feasibility: The success rate of areola preservation (based on negative second frozen section), surgical complication rates (e.g., infection, tissue necrosis).
Early Effectiveness: The rate of cancer returning in the breast/chest wall area within 3 years (local recurrence).
Patient-Reported Outcomes: Patient satisfaction with their breasts and well-being, measured by the BREAST-Q questionnaire before and after surgery.
Why This Study is Important:
This is the first prospective study to systematically evaluate this new surgical approach. The results will provide crucial preliminary data on safety and early outcomes. If the findings are promising, they will form the foundation for designing a larger, controlled trial in the future. Ultimately, this research could lead to a new option that offers women better cosmetic results and improved quality of life after mastectomy.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jingxin Jiang, MD
- Phone Number: +86-1356711447
- Email: blwangke@126.com
Study Contact Backup
- Name: Bing Yang, MD
- Phone Number: +86-18868112181
- Email: 11718405@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female, age ≥ 18 years.
- Pathologically confirmed primary invasive breast carcinoma or ductal carcinoma in situ (DCIS).
- Clinical tumor stage cTis-2, N0-2, M0 (AJCC 8th Edition).
- Planned for therapeutic nipple-sparing mastectomy (NSM) with immediate reconstruction.
- Intraoperative frozen section confirms involvement of the nipple core tissue by invasive carcinoma or DCIS.
- ECOG performance status 0-1.
- Willing and voluntarily provide written informed consent.
Exclusion Criteria:
- Clinical or radiological suspicion of areola or skin involvement.
- Inflammatory breast cancer.
- Pregnancy or lactation.
- Any severe medical or psychiatric condition that, in the investigator's judgment, would preclude safe participation or compliance.
- Severe uncontrolled comorbidities with a life expectancy of less than 5 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Areola Preservation & Nipple Reconstruction Group
Patients with intraoperatively confirmed nipple involvement during nipple-sparing mastectomy, who receive areola-preserving surgery (pending negative second frozen section of the peri-areolar margin) combined with immediate nipple reconstruction via a local flap technique (e.g., purse-string suture), followed by immediate breast reconstruction.
|
This is a combined surgical procedure for patients with intraoperative nipple involvement during nipple-sparing mastectomy.
After resection of the involved nipple, a full-thickness peri-areolar tissue margin is harvested for a second intraoperative frozen section.
If the margin is negative for carcinoma, the areola skin is preserved.
An immediate nipple reconstruction is then performed using a local skin flap technique (e.g., purse-string suture).
This is followed by standard immediate breast reconstruction (implant-based or autologous).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Local Recurrence Rate
Time Frame: 3 years post-surgery
|
The incidence of local recurrence in the ipsilateral chest wall/skin or residual breast tissue, assessed by clinical examination and imaging (breast ultrasound and/or MRI), with pathological confirmation for suspected cases.
|
3 years post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of Successful Areola Preservation
Time Frame: Intraoperative
|
The proportion of patients in whom the areola is successfully preserved, defined as having a negative result on the second intraoperative frozen section of the peri-areolar margin.
|
Intraoperative
|
|
Incidence of Postoperative Complications
Time Frame: Within 90 days post-surgery
|
The rate of surgical complications, including but not limited to areolar skin necrosis (partial/full), infection, seroma, hematoma, and implant loss/failure.
|
Within 90 days post-surgery
|
|
Change in Patient-Reported Satisfaction and Well-being
Time Frame: Baseline, 6, 12, 24, and 36 months post-surgery
|
Change in scores from baseline as measured by the validated BREAST-Q questionnaire modules (Satisfaction with Breasts, Psychosocial, Sexual, and Physical Well-being).
|
Baseline, 6, 12, 24, and 36 months post-surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ke Wang, MD, Department of Breast Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Breast Carcinoma In Situ
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Skin Diseases
- Breast Diseases
- Carcinoma
- Neoplasms, Ductal, Lobular, and Medullary
- Carcinoma in Situ
- Skin and Connective Tissue Diseases
- Breast Neoplasms
- Carcinoma, Intraductal, Noninfiltrating
Other Study ID Numbers
- APRESERVE-2025-1471
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Areola-Preserving Nipple-Sparing Mastectomy with Immediate Nipple Reconstruction
-
University Hospital, MontpellierRecruiting
-
Peking University People's HospitalRecruiting
-
University of MiamiActive, not recruitingBreast Cancer | Ductal CarcinomaUnited States
-
Guangdong Provincial Hospital of Traditional Chinese...Enrolling by invitationBreast Cancer | Breast ReconstructionChina
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
KK Women's and Children's HospitalRecruitingBreast Cancer Early Stage Breast Cancer (Stage 1-3)Singapore
-
Karolinska University HospitalKarolinska Institutet; LifeCellCompletedBreast CancerSweden, United Kingdom
-
Beaumont HospitalRoyal College of Surgeons, IrelandNot yet recruitingBreast Cancer | Robotic Surgery | Breast Reconstruction | Hereditary Breast/Ovarian Cancer (brca1, brca2)
-
Severance HospitalSamsung Medical Center; Asan Medical Center; Kyungpook National University Chilgok...Active, not recruitingBreast Neoplasms | Benign Breast Disease | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene Mutation | Germline Mutation AbnormalityKorea, Republic of
-
Changhua Christian HospitalMinistry of Science and Technology, Taiwan; Intuitive SurgicalRecruiting